Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.

What the trial testedas reported · 26,284 people · 2026

No range given

−36%

Bigger than 8 in 10 for cardiovascular events

As reported

OR 0.64, no interval

the abstract, start to end

… effect on cardiovascular events (OR = 0.64; p = 0.006).

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

Cardiovascular events

OR 0.64

GLP-1 receptor agonistsCardiovascular events

GLP-1 receptor agonists × cardiovascular eventshelps?mixed

unlikelylikely

0.50not counted

← favours treatmentfavours comparator →

more certainless certain

1 / 5